Alkermes News

Analysts Are Bullish on These Healthcare Stocks: Atricure (ATRC), Alkermes (ALKS)

TipRanksApr 29 07:18 ET

Express News | Alkermes Expects To Initiate Vibrance-2 Phase 2 Study In Narcolepsy Type 2 In 2H 2024

Moomoo 24/7Apr 24 07:05 ET

Express News | Alkermes Initiates Vibrance-1 Phase 2 Study Of ALKS 2680 For Narcolepsy Type 1

Moomoo 24/7Apr 24 07:04 ET

Express News | Alkermes PLC: Expects to Initiate Vibrance-2, a Planned Phase 2 Study in Patients With Narcolepsy Type 2, in Second Half of 2024

Moomoo 24/7Apr 24 07:00 ET

Express News | Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating Alks 2680 for the Treatment of Narcolepsy Type 1

Moomoo 24/7Apr 24 07:00 ET

Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1

DUBLIN, April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared

AlkermesApr 24 00:00 ET

Alkermes (NASDAQ:ALKS) Shareholders Have Endured a 20% Loss From Investing in the Stock a Year Ago

The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. That

Simply Wall StApr 23 13:50 ET

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)

TipRanksApr 19 06:30 ET

Alkermes Price Target Maintained With a $35.00/Share by HC Wainwright & Co.

Alkermes Price Target Maintained With a $35.00/Share by HC Wainwright & Co.

Dow JonesApr 19 06:27 ET

Express News | HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $35 Price Target

Moomoo 24/7Apr 19 06:17 ET

Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)

TipRanksApr 18 01:10 ET

Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Yahoo FinanceApr 17 10:01 ET

Alkermes to Report First Quarter Financial Results on May 1, 2024

DUBLIN, April 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to discuss the company

AlkermesApr 17 00:00 ET

Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)

TipRanksApr 12 01:41 ET

Hold Rating on Alkermes Amid Promising ALKS 2680 Data and Regulatory Challenges

TipRanksApr 12 01:38 ET

Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study

Yahoo FinanceApr 11 10:15 ET

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), DocGo (DCGO) and Alkermes (ALKS)

TipRanksApr 10 07:20 ET

Balanced Hold Rating for Alkermes Amidst Promising Data and Development Risks

TipRanksApr 10 06:26 ET

Buy Rating Affirmed for Alkermes on Promising ALKS 2680 Clinical Trial Results and Growth Potential

TipRanksApr 9 20:55 ET

Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says

On Tuesday, Alkermes plc (NASDAQ:ALKS) revealed topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680 for

BenzingaApr 9 14:23 ET